Department of Medicine

Department of Medicine

  Division of Cardiology

[Return To Index page]
photo Michael A. Shullo, PharmD

Associate Professor of Pharmacy and Therapeutics

Associate Director, Cardiac Transplantation

Director of Pharmacotherapy, Artificial Heart Program

Associate Professor, Department of Pharmacy and Therapeutics


Phone: 412-864-3776

Office: University of Pittsburgh
Presbyterian Hosp, 346.3
Pittsburgh, PA 15213
Phone: 412-864-3776
Research Interest
Dr. Shullo's research interests include immunosuppressive therapies, and clinical outcomes in solid organ transplantation and mechanical support.
Clinical Interest
Dr. Shullo's clinical practice interests include Solid Organ Transplantation, immunology, immunosuppression, mechanical support, and pharmacology.
Educational Interest
Dr. Shullo's academic interests in teaching are focused on producing pharmacists and physicians with the educational foundation and clinical skills to be lifelong contributors to the professions of pharmacy and medicine . He employs an active learning method to educate students, residents, and fellows in multiple areas of the curriculum and clinical training. Dr. Shullo is also a preceptor of a full complement of clerkship students, residents and fellows in the area of Transplantation. Additionally, Dr. Shullo serves as the Program Director for the Transplant Specialty Pharmacy Residency PGY2 at UPMC Presbyterian
For my complete bibliography, Click Here.
Selected Publications:
Ensor CR, Trofe-Clark J, Gabardi S, McDevitt-Potter LM, Shullo MA. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy. 2011; 31(11): 1111-29.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman, D, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29(8): 914-56.
Teuteberg JJ, Shullo MA, Zomak R, Toyoda Y, McNamara DM, Bermudez C, Kormos RL, McCurry KR. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010; 10(2): 382-8.
Jennings DL, Horn ET, Lyster H, Panos AL, Teuteberg JJ, Lehmkuhl HB, Perez A, Shullo MA. Assessing Anticoagulation Practice Patterns in Patients on Durable Mechanical Circulatory Support Devices: An International Survey. ASAIO J. 2016; 62(1): 28-32.
Kormos RL, Shullo M, Kormos RL, Lockard K, Zomak R, Simon MA, Bermudez C, Bhama J, McNamara D, Toyoda Y, Teuteberg JJ. Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann Thorac Surg. 2011; 91(5): 1348-54.
Teuteberg JJ, Shullo M, Zomak R, McNamara D, McCurry K, Kormos RL. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant. 2008; 22(6): 730-7.
Lampert BC, Teuteberg JJ, Shullo MA, Holtz J, Smith KJ. Cost-effectiveness of routine surveillance endomyocardial biopsy after 12 months post-heart transplantation. Circ Heart Fail. 2014; 7(5): 807-13.
Chivukula S, Shullo MA, Kormos RL, Bermudez CA, McNamara DM, Teuteberg JJ. Cancer-free survival following alemtuzumab induction in heart transplantation. Transplant Proc. 2014; 46(5): 1481-8.